Ethereum faced significant institutional pressure in October, with spot ETFs losing about $1.61 billion, led by BlackRock's ETHA fund accounting for nearly 88% of withdrawals. This outflow contributed to ETH's drop to around $2,179 before a modest recovery brought it near the key resistance zone of $2,300–$2,320. A sustained breakout above this level could lead to gains toward $2,350 and $2,400, while failure to hold $2,300 may see support tested near $2,250 and lower. Institutional demand remains cautious, but developments like ETH staking and network upgrades could influence future recovery prospects.
Ethereum's October spot ETF outflows reached about $1.61 billion, with BlackRock's ETHA fund accounting for nearly 88% of withdrawals, providing context for its price movements. For readers following cryptocurrency markets, here is Pluang's snapshot as of Nov 02, 2026 18:41 WIB: out of 50 major cryptocurrencies, 5 rose and 44 fell today. Notable movers include CRV at Rp4,973 with a 3.88% decline and a 57% sell order activity, CAKE at Rp34,538 with a 3.88% drop but 94% buy order activity, and SNX at Rp3,230 down 3.32% with 74% sell order activity.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against Tigo Energy, Fluence Energy, and Anavex Life Sciences. The lawsuits allege these companies made false or misleading stat...
Heineken N.V. has repurchased a total of 9,510,681 shares under the second tranche of its €1.5 billion share buyback program, spending €679.2 million as of October 30, 2026. The company bought 159,700 shares on the exchange and 160,530 shares from He...
Alvotech, a global biotech company specializing in biosimilars, announced its management team will participate in several investor conferences in November 2026, including events in London, Oslo, and Stockholm. These presentations and fireside chats w...
Alvotech, a global biotech company specializing in biosimilar medicines, announced its management team will participate in several investor conferences throughout November 2026. These include events in London, Oslo, and Stockholm, featuring presentat...
Alvotech, a global biotechnology company specializing in biosimilar medicines, will participate in four international investor conferences in November held in the UK, Norway, and Sweden. These events include presentations and analyst discussions host...
